Cutaneous  	Cutaneous  	 JJ	B-NP
metastases  	metastases  	 NN	I-NP
from  	from  	 IN	O
breast  	breast  	 JJ	B-NP
carcinoma 	carcinoma 	 NN	I-NP
:  	:  	 :	O
calretinin  	calretinin  	 JJ	B-NP
expression  	expression  	 NN	I-NP
and  	and  	 CC	O
estrogen 	estrogen 	 NN	B-NP
,  	,  	 ,	O
progesterone  	progesterone  	 NN	B-NP
and  	and  	 CC	O
Her2 	Her2 	 CD	B-NP
/ 	/ 	 CD	O
neu  	neu  	 JJ	B-NP
status  	status  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
metastases 	metastases 	 NN	I-NP
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
primary  	primary  	 JJ	B-NP
cutaneous  	cutaneous  	 JJ	I-NP
apocrine  	apocrine  	 JJ	I-NP
tumors  	tumors  	 NNS	I-NP
Recently 	Recently 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
demonstrated  	demonstrated  	 VBN	O
how  	how  	 WRB	O
apocrine  	apocrine  	 JJ	B-NP
glands 	glands 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
several  	several  	 JJ	O
cutaneous  	cutaneous  	 JJ	B-NP
apocrine  	apocrine  	 JJ	I-NP
tumors 	tumors 	 NNS	I-NP
,  	,  	 ,	O
do  	do  	 VBP	O
not  	not  	 RB	O
express  	express  	 VB	O
calretinin 	calretinin 	 NNS	B-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
report 	report 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
studied  	studied  	 VBD	O
calretinin  	calretinin  	 JJ	B-NP
immunoexpression  	immunoexpression  	 NN	I-NP
in  	in  	 IN	O
33  	33  	 CD	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
cutaneous  	cutaneous  	 JJ	B-NP
metastases  	metastases  	 NN	I-NP
of  	of  	 IN	I-NP
ductal  	ductal  	 JJ	I-NP
breast  	breast  	 NN	I-NP
carcinoma 	carcinoma 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 RB	O
in  	in  	 IN	O
seven  	seven  	 CD	O
primary  	primary  	 JJ	B-NP
cutaneous  	cutaneous  	 JJ	I-NP
apocrine  	apocrine  	 JJ	I-NP
tumors 	tumors 	 NNS	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
also  	also  	 RB	O
tested  	tested  	 VBN	O
the  	the  	 DT	O
hormonal  	hormonal  	 JJ	B-NP
status  	status  	 NN	I-NP
of  	of  	 IN	O
all  	all  	 DT	O
cases  	cases  	 NNS	O
for  	for  	 IN	O
estrogen  	estrogen  	 JJ	B-NP
receptors  	receptors  	 NNS	I-NP
( 	( 	 -LRB-	O
ER 	ER 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
progesterone  	progesterone  	 JJ	B-NP
receptors  	receptors  	 NNS	I-NP
( 	( 	 -LRB-	O
PR 	PR 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
ERRB2 	ERRB2 	 NNP	B-NP
.  	.  	 .	O
From  	From  	 IN	O
the  	the  	 DT	O
33  	33  	 CD	O
metastases 	metastases 	 NN	B-NP
,  	,  	 ,	O
26  	26  	 CD	O
( 	( 	 -LRB-	O
78.79 	78.79 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
cases  	cases  	 NNS	O
were  	were  	 VBD	O
calretinin-negative  	calretinin-negative  	 JJ	B-NP
and  	and  	 CC	O
seven  	seven  	 CD	O
cases  	cases  	 NNS	O
expressed  	expressed  	 VBD	O
the  	the  	 DT	O
marker 	marker 	 NN	O
.  	.  	 .	O
Five  	Five  	 CD	O
( 	( 	 -LRB-	O
15.15 	15.15 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
cases  	cases  	 NNS	O
were  	were  	 VBD	O
triple-negative  	triple-negative  	 JJ	B-NP
( 	( 	 -LRB-	O
ER- 	ER- 	 NNP	B-NP
,  	,  	 ,	O
PR- 	PR- 	 NNP	B-NP
,  	,  	 ,	O
Herceptest- 	Herceptest- 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Of  	Of  	 IN	O
these  	these  	 DT	O
five  	five  	 CD	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
three  	three  	 CD	O
cases  	cases  	 NNS	O
were  	were  	 VBD	O
calretinin+  	calretinin+  	 CD	B-NP
and  	and  	 CC	O
two  	two  	 CD	O
cases  	cases  	 NNS	O
were  	were  	 VBD	O
calretinin- 	calretinin- 	 JJ	O
.  	.  	 .	O
Three  	Three  	 CD	O
out  	out  	 IN	O
of  	of  	 IN	O
the  	the  	 DT	O
seven  	seven  	 CD	O
cases  	cases  	 NNS	O
that  	that  	 WDT	O
expressed  	expressed  	 VBD	O
calretinin  	calretinin  	 RB	O
were  	were  	 VBD	O
triple-negative 	triple-negative 	 JJ	B-NP
.  	.  	 .	O
From  	From  	 IN	O
the  	the  	 DT	O
seven  	seven  	 CD	O
primary  	primary  	 JJ	B-NP
cutaneous  	cutaneous  	 JJ	I-NP
apocrine  	apocrine  	 JJ	I-NP
tumors 	tumors 	 NNS	I-NP
,  	,  	 ,	O
only  	only  	 RB	O
one  	one  	 CD	O
showed  	showed  	 VBD	O
focal  	focal  	 JJ	B-NP
expression  	expression  	 NN	I-NP
of  	of  	 IN	I-NP
calretinin 	calretinin 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
six  	six  	 CD	O
of  	of  	 IN	O
them  	them  	 PRP	O
showed  	showed  	 VBD	O
a  	a  	 DT	O
triple-negative  	triple-negative  	 JJ	B-NP
immunophenotype 	immunophenotype 	 NN	I-NP
.  	.  	 .	O
Only  	Only  	 RB	O
the  	the  	 DT	O
ER+ 	ER+ 	 NNP	B-NP
,  	,  	 ,	O
PR+  	PR+  	 CD	B-NP
case  	case  	 NN	O
showed  	showed  	 VBD	O
morphologic  	morphologic  	 JJ	B-NP
features  	features  	 NNS	I-NP
on  	on  	 IN	O
an  	an  	 DT	O
in  	in  	 FW	O
situ  	situ  	 FW	B-NP
apocrine  	apocrine  	 FW	I-NP
carcinoma 	carcinoma 	 FW	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
concluded  	concluded  	 VBD	O
that  	that  	 IN	O
our  	our  	 PRP$	O
findings  	findings  	 NNS	O
support  	support  	 VBP	O
the  	the  	 DT	O
value  	value  	 NN	O
of  	of  	 IN	O
calretinin  	calretinin  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
differential  	differential  	 JJ	B-NP
diagnosis  	diagnosis  	 NN	I-NP
between  	between  	 IN	O
a  	a  	 DT	O
metastasis  	metastasis  	 NN	B-NP
from  	from  	 IN	O
breast  	breast  	 JJ	B-NP
carcinoma  	carcinoma  	 NN	I-NP
into  	into  	 IN	O
the  	the  	 DT	O
skin  	skin  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
primary  	primary  	 JJ	B-NP
cutaneous  	cutaneous  	 FW	I-NP
apocrine  	apocrine  	 FW	I-NP
carcinoma  	carcinoma  	 FW	I-NP
( 	( 	 -LRB-	O
CAC 	CAC 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
especially  	especially  	 RB	O
in  	in  	 IN	O
triple-negative  	triple-negative  	 JJ	B-NP
cases 	cases 	 NNS	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
hormonal  	hormonal  	 JJ	B-NP
markers  	markers  	 NN	I-NP
plus  	plus  	 CC	O
calretinin  	calretinin  	 NNS	B-NP
would  	would  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
sufficient  	sufficient  	 JJ	O
to  	to  	 TO	O
discriminate  	discriminate  	 VB	O
between  	between  	 IN	O
both  	both  	 DT	O
diagnostic  	diagnostic  	 JJ	B-NP
possibilities 	possibilities 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
they  	they  	 PRP	O
are  	are  	 VBP	O
probably  	probably  	 RB	O
better  	better  	 RBR	O
used  	used  	 VBN	O
when  	when  	 WRB	O
integrated  	integrated  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
immunohistochemical  	immunohistochemical  	 JJ	B-NP
panel 	panel 	 NN	I-NP
.  	.  	 .	O
